GlassScriptPhysician profile
Albert Jung
NPI 1457518854
$7,404.88
in general payments reported to CMS, 2019-2025
22 companies · $148 in 2025
The $148 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $372 · 2020: $2,983 · 2021: $1,617 · 2022: $1,426 · 2023: $593 · 2024: $265 · 2025: $148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,006.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,006.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $2,315.00 | 2020 | |
| Novartis Pharmaceuticals Corporation | $1,296.81 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,130.66 | 2020-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $628.86 | 2020-2023 | Farxiga |
| Janssen Pharmaceuticals, INC | $504.92 | 2021-2023 | Xarelto |
| Amgen INC. | $490.36 | 2019-2025 | Repatha, Repatha |
| Abbott Laboratories | $170.85 | 2019 | |
| Janssen Scientific Affairs, LLC | $143.05 | 2024 | Xarelto |
| Kowa Pharmaceuticals America, INC. | $124.75 | 2021-2023 | Livalo |
| Penumbra, INC. | $122.92 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $81.33 | 2022-2023 | |
| Amarin Pharma, INC. | $69.71 | 2020-2022 | |
| Pfizer INC. | $65.26 | 2019-2021 | |
| Kestra Medical Technology Services, INC. | $46.07 | 2025 | Assure Wcd |
| Kiniksa Pharmaceuticals, LTD. | $41.03 | 2023 | Arcalyst |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $39.39 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $34.72 | 2021-2025 | Camzyos |
| Merck Sharp & Dohme LLC | $24.34 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $23.00 | 2024 | Arcalyst |
| Vifor Pharma, INC. | $19.92 | 2021 | |
| Arbor Pharmaceuticals, INC. | $17.14 | 2021 | |
| Novo Nordisk INC | $14.79 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Jung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.